Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94.3Revenue $M40.0Net Margin (%)3.4Altman Z-Score9.2
Enterprise Value $M-3.1EPS $0.4Operating Margin %-3.9Piotroski F-Score5
P/E(ttm)86.9Beneish M-Score-1.7Pre-tax Margin (%)1.9Higher ROA y-yN
Price/Book0.810-y EBITDA Growth Rate %--Quick Ratio12.8Cash flow > EarningsY
Price/Sales2.75-y EBITDA Growth Rate %--Current Ratio14.4Lower Leverage y-yY
Price/Free Cash Flow18.4y-y EBITDA Growth Rate %-100.0ROA % (ttm)1.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)1.1Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M9.5ROIC % (ttm)-1.4Gross Margin Increase y-yN

Gurus Latest Trades with GENC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GENCJohn Keeley 2010-03-31 Sold Out $6.9 - $7.8
($7.31)
$ 9.9136%Sold Out0
GENCJohn Keeley 2009-09-30 Buy $6.38 - $8.35
($7.23)
$ 9.9137%New holding30,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GENC is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GENC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Houtkin Sherry10% Owner 2015-05-06Sell70,000$9.27.72 view
LYONS JEANNE MSecretary 2015-03-16Sell985$9.781.33 view
LYONS JEANNE MSecretary 2015-03-16Sell985$9.781.33 view
Houtkin Sherry10% Owner 2014-12-08Sell2,948$9.721.95 view
Houtkin Sherry10% Owner 2014-12-02Sell5,000$9.93-0.2 view
Houtkin Sherry10% Owner 2014-11-25Sell200,000$9.257.14 view
Houtkin Sherry10% Owner 2014-09-04Sell29$10.19-2.75 view
Houtkin Sherry10% Owner 2014-09-02Sell5,000$10.18-2.65 view
Houtkin Sherry10% Owner 2014-08-26Sell5,346$10.23-3.13 view
Houtkin Sherry10% Owner 2014-08-21Sell8,392$10.18-2.65 view

Press Releases about GENC :

    Quarterly/Annual Reports about GENC:

    News about GENC:

    Articles On GuruFocus.com
    Winning with the Net Current Asset Value Approach to Stocks Sep 04 2013 
    comment on GENC Aug 24 2012 
    comment on GENC Aug 13 2012 
    comment on GENC Jul 11 2012 
    comment on GENC Jul 11 2012 
    comment on GENC Jul 11 2012 
    Ben Graham Net-Net Newsletter: TSR (TSRI) One Year Later Apr 09 2012 
    “Assign Yourself the Right Story” Mar 05 2012 
    comment on GENC Mar 05 2012 
    Ben Graham Net-Net Newsletter: Gencor (GENC) One Year Later Feb 29 2012 

    More From Other Websites
    Articles of Association for Genmab A/S May 22 2015
    Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA May 21 2015
    Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash... May 20 2015
    Report Pursuant to Section 28a of the Danish Securities Trading Act May 20 2015
    GENCOR INDUSTRIES INC Financials May 19 2015
    Genmab Enters Commercial DuoBody® Technology Agreement with BioNTech in Field of Immuno-oncology May 19 2015
    HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting May 13 2015
    Genmab Announces Financial Results for the First Quarter of 2015 May 12 2015
    10-Q for Gencor Industries, Inc. May 10 2015
    GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2015
    Gencor posts 2Q profit May 08 2015
    Gencor posts 2Q profit May 08 2015
    GENCOR INDUSTRIES INC Files SEC form 10-Q, Quarterly Report May 08 2015
    Gencor Releases Second Quarter Fiscal 2015 Results May 08 2015
    First Quarter 2015 Net Sales Figures for Arzerra® (Ofatumumab) May 06 2015
    Genmab Announces Phase III Study of Arzerra® Met Primary Endpoint of Improved Progression-Free... Apr 27 2015
    Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen Apr 16 2015
    Articles of Association for Genmab A/S Apr 01 2015
    Genmab's Total Number of Voting Rights and Total Share Capital Mar 31 2015
    Genmab's Total Number of Voting Rights and Total Share Capital Mar 31 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK